\uff5e ³Ô¹Ï±¬ÁÏ eConsent\u304c\u30a4\u30f3\u30d5\u30a9\u30fc\u30e0\u30c9\u30b3\u30f3\u30bb\u30f3\u30c8\u306e\u4f5c\u6210\u3001\u5b8c\u4e86\u3001\u30ec\u30d3\u30e5\u30fc\u3092\u7c21\u7d20\u5316\u3057\u3001<\/p>\n
\u52b9\u7387\u3068\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u3092\u5411\u4e0a \uff5e<\/p>\n
<\/p>\n
2021\u5e7410\u670815\u65e5<\/p>\n
³Ô¹Ï±¬ÁÏ Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
³Ô¹Ï±¬ÁÏ Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b ³Ô¹Ï±¬ÁÏ) \u306f\u3001Celerion\u793e\u304c\u3001\u7b2cI\u76f8\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3051\u308b\u540c\u610f\u53d6\u5f97\u306e\u96fb\u5b50\u5316\u3092\u884c\u3046\u305f\u3081\u306b\u3001My³Ô¹Ï±¬ÁÏ for Patients<\/a><\/strong>\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e³Ô¹Ï±¬ÁÏ eConsent<\/a><\/strong>\u3092\u63a1\u7528\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Celerion\u793e\u306f\u3001³Ô¹Ï±¬ÁÏ eConsent\u306e\u5c0e\u5165\u306b\u3088\u308a\u3001\u624b\u52d5\u3084\u7d19\u30d9\u30fc\u30b9\u3067\u306e\u30a4\u30f3\u30d5\u30a9\u30fc\u30e0\u30c9\u30b3\u30f3\u30bb\u30f3\u30c8\u304b\u3089\u5b8c\u5168\u306b\u30c7\u30b8\u30bf\u30eb\u306a\u30d7\u30ed\u30bb\u30b9\u3078\u3068\u79fb\u884c\u3057\u3064\u3064\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u4eca\u307e\u3067\u306b\u8907\u6570\u306e\u8a66\u9a13\u3067³Ô¹Ï±¬ÁÏ eConsent\u3092\u5229\u7528\u3057\u3066\u304a\u308a\u3001200\u4eba\u4ee5\u4e0a\u306e\u88ab\u9a13\u8005\u304b\u3089\u540c\u610f\u3092\u5f97\u3066\u3044\u307e\u3059\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001³Ô¹Ï±¬ÁÏ\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n Celerion\u793e\u306e\u30b5\u30a4\u30a8\u30f3\u30c6\u30a3\u30d5\u30a3\u30c3\u30af\u30af\u30ea\u30cb\u30ab\u30eb\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u62c5\u5f53\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3067\u3042\u308bStaci McDonald\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u306e\u5f71\u97ff\u3067\u88ab\u9a13\u8005\u3068\u63a5\u89e6\u3067\u304d\u308b\u6642\u9593\u304c\u5236\u9650\u3055\u308c\u3066\u3044\u305f\u3053\u3068\u304b\u3089\u3001\u65b0\u3057\u3044\u30c7\u30b8\u30bf\u30eb\u306a\u65b9\u6cd5\u3092\u5c0e\u5165\u3057\u3001\u9069\u5207\u306a\u540c\u610f\u53d6\u5f97\u306b\u95a2\u3059\u308b\u898f\u5236\u8981\u4ef6\u3092\u5b8c\u5168\u306b\u9075\u5b88\u3057\u305f\u3046\u3048\u3067\u8a66\u9a13\u3092\u9032\u3081\u3066\u3044\u304f\u5fc5\u8981\u304c\u3042\u308a\u307e\u3057\u305f\u3002³Ô¹Ï±¬ÁÏ eConsent\u306f\u4f7f\u3044\u3084\u3059\u3044\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3067\u3001\u30da\u30fc\u30b9\u304c\u901f\u3044\u5f53\u793e\u306e\u74b0\u5883\u306b\u5bfe\u5fdc\u3057\u3064\u3064\u3001\u8a66\u9a13\u624b\u9806\u306b\u5bfe\u3059\u308b\u88ab\u9a13\u8005\u306e\u7406\u89e3\u5ea6\u5411\u4e0a\u3082\u652f\u63f4\u3057\u3066\u304f\u308c\u307e\u3059\u3002\u3053\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u5c0e\u5165\u306f\u30b9\u30e0\u30fc\u30ba\u306b\u9032\u307f\u3001\u8a66\u9a13\u30c1\u30fc\u30e0\u3001\u73fe\u5834\u30b9\u30bf\u30c3\u30d5\u3001\u88ab\u9a13\u8005\u304b\u3089\u306e\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3082\u597d\u8a55\u3067\u3059\u3002\u300d<\/p>\n \u65e9\u671f\u81e8\u5e8a\u8a66\u9a13\u30b5\u30fc\u30d3\u30b9\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u30ea\u30fc\u30c0\u30fc\u3067\u3042\u308bCelerion\u793e\u306f\u3001³Ô¹Ï±¬ÁÏ SiteVault<\/a><\/strong>\u3092\u4f7f\u7528\u3057\u3066\u3001\u30a4\u30f3\u30d5\u30a9\u30fc\u30e0\u30c9\u30b3\u30f3\u30bb\u30f3\u30c8\u30d5\u30a9\u30fc\u30e0 (ICF) \u306e\u30aa\u30fc\u30b5\u30ea\u30f3\u30b0\u3001\u7ba1\u7406\u3001\u914d\u5e03\u3092\u30c7\u30b8\u30bf\u30eb\u3067\u884c\u3063\u3066\u3044\u307e\u3059\u3002\u305d\u3057\u3066\u3001\u88ab\u9a13\u8005\u306feConsent\u6587\u66f8\u306b\u5b89\u5168\u306b\u30a2\u30af\u30bb\u30b9\u3057\u3001\u30e2\u30d0\u30a4\u30eb\u30c7\u30d0\u30a4\u30b9\u3092\u4ecb\u3057\u3066\u540c\u610f\u30d7\u30ed\u30bb\u30b9\u3092\u5b8c\u4e86\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u3001\u30c9\u30ad\u30e5\u30e1\u30f3\u30c8\u306e\u7167\u5408\u4f5c\u696d\u304c\u7c21\u7d20\u5316\u3055\u308c\u3001\u65bd\u8a2d\u306e\u7ba1\u7406\u8ca0\u62c5\u304c\u8efd\u6e1b\u3055\u308c\u307e\u3059\u3002\u30b7\u30fc\u30e0\u30ec\u30b9\u306a\u60c5\u5831\u306e\u6d41\u308c\u306b\u3088\u308a\u3001Celerion\u793e\u306f\u540c\u610f\u306e\u30b9\u30c6\u30fc\u30bf\u30b9\u3092\u5b8c\u5168\u306b\u53ef\u8996\u5316\u3057\u3001\u8a66\u9a13\u306e\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u304a\u3088\u3073\u76e3\u8996\u72b6\u6cc1\u3092\u6539\u5584\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002<\/p>\n ³Ô¹Ï±¬ÁÏ Systems\u793e\u306eMy³Ô¹Ï±¬ÁÏ for Patients\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bTim Davis\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cCelerion\u793e\u306f\u3001\u60a3\u8005\u4e2d\u5fc3\u306e\u30da\u30fc\u30d1\u30fc\u30ec\u30b9\u306a\u81e8\u5e8a\u8a66\u9a13\u3092\u53ef\u80fd\u306b\u3059\u308b\u30c7\u30b8\u30bf\u30eb\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u5229\u7528\u3059\u308b\u3053\u3068\u3067\u3001\u696d\u754c\u5168\u4f53\u306e\u5354\u529b\u4f53\u5236\u3092\u9032\u3081\u3066\u3044\u307e\u3059\u3002³Ô¹Ï±¬ÁÏ eConsent\u306f\u3001\u88ab\u9a13\u8005\u306b\u76f4\u611f\u7684\u3067\u30c7\u30b8\u30bf\u30eb\u306a\u4f53\u9a13\u3092\u63d0\u4f9b\u3057\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u304c\u8a66\u9a13\u5b9f\u65bd\u65bd\u8a2d\u3084IRB\u3068\u306e\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u5bb9\u6613\u306b\u3059\u308b\u3053\u3068\u3067\u3001\u95a2\u4fc2\u8005\u5168\u54e1\u306e\u30a4\u30f3\u30d5\u30a9\u30fc\u30e0\u30c9\u30b3\u30f3\u30bb\u30f3\u30c8\u30d7\u30ed\u30bb\u30b9\u3092\u6539\u5584\u3057\u307e\u3059\u3002\u300d<\/p>\n <\/p>\n \u3010<\/strong>³Ô¹Ï±¬ÁÏ Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward-looking Statements\u3011 Celerion\u793e\u304c\u3001\u7b2cI\u76f8\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3051\u308b\u540c\u610f\u53d6\u5f97\u306e\u96fb\u5b50\u5316\u3092\u884c\u3046\u305f\u3081\u306b\u3001My³Ô¹Ï±¬ÁÏ for Patients\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e³Ô¹Ï±¬ÁÏ eConsent\u3092\u63a1\u7528\u3002\u624b\u52d5\u3084\u7d19\u30d9\u30fc\u30b9\u3067\u306e\u30a4\u30f3\u30d5\u30a9\u30fc\u30e0\u30c9\u30b3\u30f3\u30bb\u30f3\u30c8\u304b\u3089\u5b8c\u5168\u306b\u30c7\u30b8\u30bf\u30eb\u306a\u30d7\u30ed\u30bb\u30b9\u3078\u3068\u79fb\u884c\u4e2d\u3002<\/p>\n","protected":false},"author":131,"featured_media":46348,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-46345","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46345"}],"collection":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=46345"}],"version-history":[{"count":3,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46345\/revisions"}],"predecessor-version":[{"id":46350,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46345\/revisions\/46350"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media\/46348"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=46345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=46345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=46345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n³Ô¹Ï±¬ÁÏ Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u30011,100\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066³Ô¹Ï±¬ÁÏ\u306f\u3001\u9867\u5ba2\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2021.This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"